S&P 500   4,337.44
DOW   34,006.88
QQQ   359.61
3 Blue Chip Safe Havens to Shield Your Portfolio
6.5 Million Americans Are DESPERATE for This New Drug from One Tiny Company (Ad)
Is Jet Blue's Descent Into Penny Stock Territory an Opportunity?
Are Gene Therapy Stocks The Market's Next Big Winners?
6.5 Million Americans Are DESPERATE for This New Drug from One Tiny Company (Ad)
3 Stocks That Flourish In The Fall
2 Must-Have Silicon Companies That Don't Make Microchips
6.5 Million Americans Are DESPERATE for This New Drug from One Tiny Company (Ad)
Buy The World’s Largest IT Infrastructure Provider For Under $20
Small Caps That Have Priced In A Hard Landing For Big Upside
S&P 500   4,337.44
DOW   34,006.88
QQQ   359.61
3 Blue Chip Safe Havens to Shield Your Portfolio
6.5 Million Americans Are DESPERATE for This New Drug from One Tiny Company (Ad)
Is Jet Blue's Descent Into Penny Stock Territory an Opportunity?
Are Gene Therapy Stocks The Market's Next Big Winners?
6.5 Million Americans Are DESPERATE for This New Drug from One Tiny Company (Ad)
3 Stocks That Flourish In The Fall
2 Must-Have Silicon Companies That Don't Make Microchips
6.5 Million Americans Are DESPERATE for This New Drug from One Tiny Company (Ad)
Buy The World’s Largest IT Infrastructure Provider For Under $20
Small Caps That Have Priced In A Hard Landing For Big Upside
S&P 500   4,337.44
DOW   34,006.88
QQQ   359.61
3 Blue Chip Safe Havens to Shield Your Portfolio
6.5 Million Americans Are DESPERATE for This New Drug from One Tiny Company (Ad)
Is Jet Blue's Descent Into Penny Stock Territory an Opportunity?
Are Gene Therapy Stocks The Market's Next Big Winners?
6.5 Million Americans Are DESPERATE for This New Drug from One Tiny Company (Ad)
3 Stocks That Flourish In The Fall
2 Must-Have Silicon Companies That Don't Make Microchips
6.5 Million Americans Are DESPERATE for This New Drug from One Tiny Company (Ad)
Buy The World’s Largest IT Infrastructure Provider For Under $20
Small Caps That Have Priced In A Hard Landing For Big Upside
S&P 500   4,337.44
DOW   34,006.88
QQQ   359.61
3 Blue Chip Safe Havens to Shield Your Portfolio
6.5 Million Americans Are DESPERATE for This New Drug from One Tiny Company (Ad)
Is Jet Blue's Descent Into Penny Stock Territory an Opportunity?
Are Gene Therapy Stocks The Market's Next Big Winners?
6.5 Million Americans Are DESPERATE for This New Drug from One Tiny Company (Ad)
3 Stocks That Flourish In The Fall
2 Must-Have Silicon Companies That Don't Make Microchips
6.5 Million Americans Are DESPERATE for This New Drug from One Tiny Company (Ad)
Buy The World’s Largest IT Infrastructure Provider For Under $20
Small Caps That Have Priced In A Hard Landing For Big Upside
NASDAQ:IMUX

Immunic (IMUX) Stock Forecast, Price & News

$1.36
0.00 (0.00%)
(As of 09/25/2023 ET)
Compare
Today's Range
$1.33
$1.41
50-Day Range
$1.36
$2.65
52-Week Range
$1.11
$11.76
Volume
150,985 shs
Average Volume
219,915 shs
Market Capitalization
$60.66 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.00

Immunic MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
267.6% Upside
$5.00 Price Target
Short Interest
Bearish
5.36% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.19) to ($1.89) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.90 out of 5 stars

Medical Sector

729th out of 963 stocks

Pharmaceutical Preparations Industry

330th out of 444 stocks


IMUX stock logo

About Immunic (NASDAQ:IMUX) Stock

Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 3 clinical for treatment of multiple sclerosis, including relapsing multiple sclerosis and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease. The company is also developing IMU-935, an inverse agonist of retinoic acid receptor-related orphan nuclear receptor gamma truncated; and IMU-856 for the restoration of the intestinal barrier function in patients suffering from diseases, such as celiac disease, inflammatory bowel disease, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases. Immunic, Inc. is headquartered in New York, New York.

IMUX Price History

IMUX Stock News Headlines

This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Wedbush Sticks to Its Buy Rating for Immunic (IMUX)
Immunic CEO says Q2 results "couldn't be better"
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Immunic (NASDAQ: IMUX)
Wedbush Keeps Their Buy Rating on Immunic (IMUX)
Recap: Immunic Q1 Earnings
Immunic Inc set to bring relief with encouraging results
Immunic: Q1 Earnings Snapshot
See More Headlines
Receive IMUX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Immunic and its competitors with MarketBeat's FREE daily newsletter.

IMUX Company Calendar

Last Earnings
8/03/2023
Today
9/25/2023
Next Earnings (Estimated)
11/02/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:IMUX
Employees
75
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$5.00
High Stock Price Forecast
$5.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+267.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

Net Income
$-120,410,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$2.56 per share

Miscellaneous

Free Float
42,588,000
Market Cap
$60.65 million
Optionable
Not Optionable
Beta
2.03
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for October 2023. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Dr. Duane D. Nash J.D. (Age 52)
    M.B.A, M.B.A., M.D., Exec. Chairman
    Comp: $433.4k
  • Dr. Daniel Vitt Ph.D. (Age 55)
    CEO, Pres & Director
    Comp: $728.4k
  • Mr. Glenn  Whaley CPAMr. Glenn Whaley CPA (Age 55)
    Chief Financial Officer
    Comp: $522.21k
  • Dr. Andreas Muehler M.D. (Age 59)
    Ph.D., Chief Medical Officer
    Comp: $599.57k
  • Dr. Hella Kohlhof (Age 50)
    Chief Scientific Officer
  • Jessica Breu
    Head of Investor Relations & Communications
  • Mr. Inderpal Singh (Age 57)
    Gen. Counsel
  • Mr. Patrick Walsh (Age 40)
    Chief Bus. Officer













IMUX Stock - Frequently Asked Questions

Should I buy or sell Immunic stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Immunic in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" IMUX shares.
View IMUX analyst ratings
or view top-rated stocks.

What is Immunic's stock price forecast for 2023?

2 Wall Street research analysts have issued 12-month price targets for Immunic's stock. Their IMUX share price forecasts range from $5.00 to $5.00. On average, they anticipate the company's stock price to reach $5.00 in the next twelve months. This suggests a possible upside of 267.6% from the stock's current price.
View analysts price targets for IMUX
or view top-rated stocks among Wall Street analysts.

How have IMUX shares performed in 2023?

Immunic's stock was trading at $1.40 on January 1st, 2023. Since then, IMUX shares have decreased by 2.9% and is now trading at $1.36.
View the best growth stocks for 2023 here
.

When is Immunic's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our IMUX earnings forecast
.

How were Immunic's earnings last quarter?

Immunic, Inc. (NASDAQ:IMUX) posted its earnings results on Thursday, August, 3rd. The company reported ($0.54) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.52) by $0.02.

What other stocks do shareholders of Immunic own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Immunic investors own include Advanced Micro Devices (AMD), Sorrento Therapeutics (SRNE), Trevena (TRVN), VBI Vaccines (VBIV), Moderna (MRNA), CymaBay Therapeutics (CBAY), NIO (NIO), NVIDIA (NVDA), TG Therapeutics (TGTX) and

What is Immunic's stock symbol?

Immunic trades on the NASDAQ under the ticker symbol "IMUX."

Who are Immunic's major shareholders?

Immunic's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Gratus Capital LLC (3.78%), Acadian Asset Management LLC (1.34%), BlackRock Inc. (0.85%), Geode Capital Management LLC (0.79%), Deep Track Capital LP (0.69%) and XTX Topco Ltd (0.49%). Insiders that own company stock include Andreas Muehler, Daniel Vitt, Duane Nash, Glenn Whaley and Joerg Neermann.
View institutional ownership trends
.

How do I buy shares of Immunic?

Shares of IMUX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Immunic's stock price today?

One share of IMUX stock can currently be purchased for approximately $1.36.

How much money does Immunic make?

Immunic (NASDAQ:IMUX) has a market capitalization of $60.65 million. The company earns $-120,410,000.00 in net income (profit) each year or ($3.44) on an earnings per share basis.

How can I contact Immunic?

Immunic's mailing address is 1200 AVENUE SUITE 200, NEW YORK NY, 10036. The official website for the company is www.immunic-therapeutics.com. The company can be reached via phone at (332) 255-9818, via email at jessica.breu@immunic.de, or via fax at 858-673-6843.

This page (NASDAQ:IMUX) was last updated on 9/26/2023 by MarketBeat.com Staff

My Account -